[PDF] Top 20 Immune system should be the target of Type 2 diabetes therapy

... of diabetes 25 ...Innate immune receptors, like Toll-like receptors (TLRs), are known to be up-regulated in the tissue affected by most inflammatory disorders and activated by both specific microbial ... See full document

... MSC therapy may represent a new paradigm for optimizing glycemic control in ...cell therapy-based strate- gies a clinical reality, it is fundamentally necessary to identify sources of MSCs that do not have ... See full document

... with type 2 ...in type 1 diabetes ...insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and ... See full document

... As type I diabetes mellitus T1DM is an auto immune disorder common in young ones and children’s in which body owns immune system is accountable for the demolition of pancreatic cells ... See full document

... Abstract: Type 2 diabetes is a complex, chronic, and progressive condition that often neces- sitates the use of multiple medications to achieve glycemic ...with type 2 diabetes, ... See full document

... combination therapy of glitazone and insulin often shows a rapid and large lowering effect in plasma glu- cose within 1 to 2 months of starting ...pioglitazone therapy, the dose of pioglitazone ... See full document

... nausea/vomiting, should seek immediate medical attention to rule out hemorrhagic/necrotizing ...metformin therapy, sulfonylurea therapy or metformin and sulfonylurea therapy combination to ... See full document

... insulin dose was kept constant, HbA 1c levels were unchanged in the placebo group (mean change, 0%) compared with reductions of –0.6% and –0.7% in the empagliflozin 10 and 25 mg groups, respectively. After week 18, the ... See full document

... had insufficient glycemic control (HbA 1c $7.0%) despite metformin and/or sulfonylurea and/or insulin therapy. With linagliptin treatment, a better reduction of blood glucose was achieved at week 24, as compared ... See full document

... As illustrated previously, clinical trial data with saxagliptin demonstrate clinical efficacy in terms of A1C, FPG, and PPG reductions when used either as monotherapy or in combination with other oral anti- hyperglycemic ... See full document

... SMBG allows patients to evaluate their responses to therapy and assess whether glycemic targets are being met. It can help in preventing hypo- glycemia and adjusting medications (particularly prandial insulin), ... See full document

... Abstract: Type 2 diabetes mellitus (T2DM) is a chronic illness that requires clinical recogni- tion and treatment of the dual pathophysiologic entities of altered glycemic control and insulin ... See full document

... A review of literature was conducted using PubMed, Google Scholar, and Medline. Several terms were used in combination, including “cardiac”, “ autonomic”, “neu- ropathy”, “ dysfunction”, “cardiomyopathy”, ... See full document

... with type 2 ...and should be implemented for all ...but should be an adjunctive to both medication and dietary ...of type 2 diabetes, as well as how populations with ... See full document

... American Diabetes Association and The European Association for the Study of Diabetes recommend metformin as the initial agent of choice in the treatment of type 2 diabetes ... See full document

... patients. Exenatide QW administra- tion does not need to be associated with a meal or a certain time of day, and dose adjustment is not necessary. Missed doses can be taken up to 4 days late. Although improvements in ... See full document

... Cell membranes are particularly susceptible to the hostility of free radicals. When the nucleus is injured, the cell loses its ability to replicate itself. The impaired cell replication results in the destabilized ... See full document

... with type 2 diabetes examined the effect of pramlinitide in a 26-week, multi-center, double-blind, placebo-controlled study (N = 499) (Gottlieb ...of diabetes was ... See full document

... world. 2 In 2013, DM was the seventh leading cause of death (causing ...that diabetes will affect 642 million in ...International Diabetes Federation, T2DM contributes for the sufferings of about 415 ... See full document

... of Type II Diabetes Mellitus, the objective is to investigate the independent effect of weight change in young adulthood on the risk of prevalent Type II diabetes mellitus among middle-aged ... See full document